New data on clinical development of deucrictibant shared at clinical conference in Budapest
A number of clinical trials of deucrictibant, a potential medicine to prevent and treat HAE, reported new data at the recent 14th C1-Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary. The pharmaceutical company Pharvaris shared the following summary of the data with HAEi:
- Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated
- First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolio
- Clinically validated biomarker assay has potential to eventually expand treatment opportunities of deucrictibant into additional forms of bradykinin-mediated angioedema
- Epidemiologic data and cognitive interviews further elucidate the unmet needs in bradykinin-mediated angioedema
Berndt Modig, Chief Executive Officer of Pharvaris, said: “Additional analyses of deucrictibant data demonstrate consistency in the clinical profile shown in both the prophylactic and on-demand treatment settings. Deucrictibant’s early-onset and durable treatment response in the on-demand setting, the maintenance of attack reduction for over a year and a half in the prophylactic setting, and the potential for deucrictibant to be used together in both the prophylactic and on-demand settings, if needed, provide additional evidence of deucrictibant’s potential in the treatment of bradykinin- mediated angioedema. Pharvaris continues to diligently execute on the deucrictibant clinical program and is planning for two pivotal data readouts in the next 18 months.”
Peng Lu MD PhD, Chief Medical Officer of Pharvaris, stated: “Deucrictibant remains the only drug in development for bradykinin-mediated angioedema that has the potential to both prevent attacks and treat them when they occur. The data from the ongoing study further bolsters the potential value proposition of deucrictibant as it provides initial evidence that a bradykinin B2 receptor antagonist can effectively manage a breakthrough attack during treatment with a B2 receptor antagonist, if it were to occur. We believe further confirming these post-hoc open-label findings in our ongoing CHAPTER-3 study would provide additional evidence on the potential of deucrictibant to help address unmet needs of people living with bradykinin-mediated angioedema.”
(Source: Pharvaris)